In 1906, a physiologist in London injected an extract of the posterior pituitary gland into a pregnant cat and watched the uterus contract. That single observation, made by Henry Dale, opened a line of research that would take nearly fifty years to reach a pure synthetic molecule, and it is still being extended today. This is the history of oxytocin: a small peptide that moved from crude gland extracts to the first laboratory-built polypeptide hormone, and then into questions about the brain that no one in 1906 could have asked.
From pituitary extracts to a named activity
The groundwork predates oxytocin itself. In 1895, George Oliver and Edward Schafer reported that an extract of the pituitary gland raised blood pressure when injected into dogs. The gland clearly did something, but the extracts were mixtures, and separating one effect from another took years of careful work.
Dale’s 1906 experiments are the usual starting point for oxytocin’s story. He showed that posterior pituitary extract drove powerful uterine contractions, and he noted that this uterus-contracting action appeared separable from the blood-pressure effect Oliver and Schafer had described. The name oxytocin comes from Greek roots meaning “swift birth,” reflecting that early observation of uterine activity. A few years later, in 1910, Isaac Ott and John Scott reported that posterior-lobe extract increased milk output, pointing to a second biological action, milk let-down, associated with the same gland region. At this stage no one had a pure substance in hand. What existed was a set of activities attributed to an extract.
Who discovered oxytocin?
The honest answer is that no single person “discovered oxytocin” as we now define it. Dale is credited with identifying and naming the uterus-contracting activity in 1906, which is why his name anchors most timelines. But the molecule behind that activity was not isolated, sequenced, or structurally defined for decades afterward. Through the 1920s and beyond, researchers worked to purify posterior-pituitary extracts and to separate two overlapping sets of effects: the pressor and antidiuretic actions that would be attributed to vasopressin, and the uterotonic and milk-ejection actions attributed to oxytocin. Crediting the discovery, then, means crediting a chain of work, with Dale at one end and the chemists who defined the actual structure at the other.
Du Vigneaud and the 1953 synthesis
The decisive chemistry came from Vincent du Vigneaud, who chaired the biochemistry department at Cornell University Medical College (now Weill Cornell Medicine). Building on his long study of sulfur-containing compounds, du Vigneaud and his colleagues determined that oxytocin is a nonapeptide, a chain of nine amino acid residues, containing a disulfide bridge between two cysteine residues that closes part of the molecule into a ring. That was a striking result on its own: most proteins known at the time ran to hundreds of residues, and here was a hormone built from a short, defined sequence.
Knowing the sequence, du Vigneaud’s group then built the molecule from scratch. In 1953 they reported the chemical synthesis of oxytocin, published in the Journal of the American Chemical Society, and showed that the synthetic material carried the biological activity of the natural hormone. It was the first synthesis of a polypeptide hormone. The achievement earned du Vigneaud the 1955 Nobel Prize in Chemistry, awarded, in the committee’s words, for work on biochemically important sulfur compounds and especially for that first synthesis. Because the same laboratory also worked on vasopressin, the two closely related pituitary peptides were often studied side by side.
From hormone to neuropeptide
Defining the structure did not close the subject; it reframed it. Oxytocin is synthesized in the paraventricular and supraoptic nuclei of the hypothalamus and released from the posterior pituitary, so it sits at the border between the nervous system and the endocrine system. That dual identity, a hormone that is also a brain-signaling peptide, pushed research in a new direction in the later twentieth century.
Much of that work has examined oxytocin’s role in social behavior. Studies in prairie voles, a species that forms lasting pair bonds, have been used to probe how oxytocin signaling relates to partner preference and attachment, with attention to receptor distribution in regions such as the nucleus accumbens. This line of research is active and often described in popular writing with tidy labels like “the love hormone.” Those labels overstate what is settled. The animal findings are genuine, but translating them into a clean account of human social behavior remains an open, contested area rather than a closed chapter. The useful summary is that oxytocin’s biology is well characterized at the level of structure and basic physiology, while its behavioral roles are still being worked out.
Research use only. Oxytocin is supplied by Vero Labs strictly as a research compound for laboratory investigation. It is not for human or animal use, and nothing here is medical, dosing, or usage guidance. Every batch is independently third-party lab-tested, with a published Certificate of Analysis (COA) available for the material.